Literature DB >> 8543977

Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate.

F Hosain1, R P Spencer, H M Couthon, G L Sturtz.   

Abstract

UNLABELLED: A methotrexate-bisphosphonate conjugate containing a peptide bond has been found to possess over five times greater antineoplastic activity against osteosarcoma in experimental animal models compared with methotrexate alone.
METHODS: The conjugate was labeled with 99mTc in the presence of stannous ions to determine biologic distribution, with special reference to osseous tissue. Biodistribution studies were carried out in mice after intravenous administration of the labeled conjugate. Radionuclide imaging of rabbits was also performed.
RESULTS: The labeled conjugate behaved like a bone-seeking agent.
CONCLUSION: The present study indicates that the concept of treating osteosarcoma or metastatic tumors of bone with this class of agents has a firm basis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8543977

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.

Authors:  Monica M Reinholz; Shawn P Zinnen; Amylou C Dueck; David Dingli; Gregory G Reinholz; Leslie A Jonart; Kathleen A Kitzmann; Amy K Bruzek; Vivian Negron; Abdalla K Abdalla; Bonnie K Arendt; Anthony J Croatt; Luis Sanchez-Perez; David P Sebesta; Harri Lönnberg; Toshiyuki Yoneda; Karl A Nath; Diane F Jelinek; Stephen J Russell; James N Ingle; Thomas C Spelsberg; Henry B F Hal Dixon; Alexander Karpeisky; Wilma L Lingle
Journal:  Bone       Date:  2010-03-15       Impact factor: 4.398

2.  188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.

Authors:  Amal A El-Mabhouh; John R Mercer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-12       Impact factor: 9.236

3.  An osteoclast-targeting agent for imaging and therapy of bone metastasis.

Authors:  Wei Liu; Asghar Hajibeigi; Mai Lin; Cynthia L Rostollan; Zoltan Kovacs; Orhan K Oz; Xiankai Sun
Journal:  Bioorg Med Chem Lett       Date:  2008-07-27       Impact factor: 2.823

4.  Relief of pain from osseous metastatic lesions.

Authors:  R P Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

Review 5.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2011-09-10       Impact factor: 15.470

6.  In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis.

Authors:  Sarah Schott; Sonia Vallet; Robert J Tower; Seema Noor; Sanjay Tiwari; Christian Schem; Christian Busch
Journal:  Invest New Drugs       Date:  2015-05-20       Impact factor: 3.850

7.  Engineering nanocages with polyglutamate domains for coupling to hydroxyapatite biomaterials and allograft bone.

Authors:  Bonnie K Culpepper; David S Morris; Peter E Prevelige; Susan L Bellis
Journal:  Biomaterials       Date:  2013-01-11       Impact factor: 12.479

Review 8.  Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.

Authors:  Hideki Hirabayashi; Jiro Fujisaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Bone as an effect compartment : models for uptake and release of drugs.

Authors:  David Stepensky; Lilach Kleinberg; Amnon Hoffman
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Bisphosphonate conjugation for bone specific drug targeting.

Authors:  Kristen B Farrell; Alexander Karpeisky; Douglas H Thamm; Shawn Zinnen
Journal:  Bone Rep       Date:  2018-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.